Related Experiment Video
Updated: Jul 29, 2025

A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice
Published on: June 22, 2022
Osteopontin in Pulmonary Hypertension
Argen Mamazhakypov1, Abdirashit Maripov2, Akpay S Sarybaev2
1Department of Internal Medicine, Excellence Cluster Cardio-Pulmonary Institute (CPI), Member of the German Center for Lung Research (DZL), Justus Liebig University of Giessen, 35392 Giessen, Germany.
Osteopontin may be a key player in pulmonary hypertension (PH) development and progression. Targeting osteopontin could offer a new therapeutic strategy for managing this complex cardiovascular disease.
Area of Science:
- Cardiovascular Research
- Pulmonary Medicine
- Molecular Biology
Background:
- Pulmonary hypertension (PH) involves elevated pulmonary arterial pressure and vascular remodeling.
- The exact causes of PH and its progression are not fully understood.
- Osteopontin is being investigated for its role in PH.
Purpose of the Study:
- To review the role of osteopontin in pulmonary hypertension pathogenesis.
- To explore osteopontin as a potential biomarker for PH severity and prognosis.
- To discuss therapeutic strategies targeting osteopontin for PH management.
Main Methods:
- Review of clinical evidence linking osteopontin to PH.
- Analysis of preclinical rodent models implicating osteopontin in PH.
- Examination of osteopontin's cellular functions in the pulmonary vasculature.
Main Results:
- Circulating osteopontin may indicate PH progression, severity, and prognosis.
- Osteopontin is implicated in maladaptive right ventricular remodeling in PH.
- Osteopontin influences key cellular processes like proliferation, migration, and inflammation.
Conclusions:
- Osteopontin plays a significant role in pulmonary vascular remodeling in PH.
- Osteopontin's involvement in PH pathogenesis warrants further investigation.
- Targeting osteopontin presents a potential therapeutic avenue for PH.
More Related Videos
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...

